Merck discontinues development on Karo's MK-6913

Karo Bio has been notified that Merck has decided to discontinue the development of MK-6913 for the treatment of hot flashes. The decision was made after an interim analysis of data from the first stage of the phase II study, initiated in December 2009, showed that the pre-defined efficacy criteria for advancement of the compound to the second stage of the study were not met. Merck is evaluating its options for future studies involving MK-6913. Karo’s collaboration with Merck covering estrogen receptors in the field of women’s health was initiated in 1997. The joint drug discovery phase in the collaboration was concluded in 2002.

About these ads